Bank of America Corp vs Crispr Therapeutics AG — how do they compare? Bank of America Corp trades at $63.93 (market cap $446.56B), while Crispr Therapeutics AG trades at $53.88 (market cap $5.17B). The key difference: Bank of America Corp is far larger — about 86.4× Crispr Therapeutics AG's market cap, and Bank of America Corp pays a 2% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| BAC | CRSP | |
|---|---|---|
Market Cap | $446.56B | $5.17B |
Volume | 55,637,172 | — |
Sector | Financials | Health |
52-Week High | $64.00 | $76.78 |
52-Week Low | $46.72 | $44.34 |
Dividend Yield | 2% | — |
Enterprise Value | — | $3.59B |
Signals from Pluang's Aura AI — not financial advice
Bank of America (BAC) trades at $64.00, up 1.31% today, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong fundamentals, including a P/E of 14.75 and net income margin of 28.21%, supported by revenue growth to $113.10 billion in 2025. Recent news highlights partnerships, hiring initiatives, and positive analyst coverage, with a consensus price target of $67.36.
Outlook remains positive with potential upside from capital returns and earnings growth, though risks include macroeconomic sensitivity and high RSI levels. Analyst consensus is strongly bullish with 64.82% buy ratings, indicating confidence in BAC's deposit franchise and operational strength amid evolving rate cycles.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Bank of America Corporation operates as a financial holding company. The Company offers saving accounts, deposits, mortgage and construction loans, cash and wealth management, certificates of deposit, investment funds, credit and debit cards, insurance, mobile, and online banking services. Bank of America serves customers worldwide.
Read more on BAC →CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →